AGY2-EGFR LDDS

**AGY2-EGFR LDDS** is a preclinical EGFR-targeted liposomal nanoparticle formulation developed at Florida A&M University for pancreatic ductal adenocarcinoma. It encapsulates AGY2, a newly synthesized fluoropyrimidine nucleoside analog, within PEGylated liposomes functionalized with the anti-EGFR monoclonal antibody cetuximab. The cetuximab surface ligand is intended to promote accumulation and uptake in EGFR-expressing pancreatic cancer cells, while liposomal delivery improves AGY2 pharmacokinetics and tumor exposure. Preclinical studies reported greater cytotoxicity than non-targeted AGY2 formulations and 5-fluorouracil in pancreatic cancer spheroid and organoid models, as well as antitumor activity in mouse models. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC13099476/))

Other names

AGY 2-EGFR LDDSAGY2-EGFR LDDSAGY-2-EGFR LDDSAnti-EGFR liposomal drug delivery system loaded with AGY2EGFR-AGY2 LNPsEGFR-AGY-2 LNPsEGFR-AGY 2 LNPs